EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants

M. J. Cardoso, L. Wyld, I. T. Rubio, M. Leidenius, G. Curigliano, B. Cutuli, L. Marotti, L. Biganzoli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally. We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it. We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL.

Original languageEnglish
Pages (from-to)90-93
Number of pages4
JournalBreast
Volume44
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Anaplastic Large-Cell Lymphoma
Breast Implants
Protective Devices
Rare Diseases
Esthetics
Drug Therapy
Mortality

Keywords

  • ALCL
  • Anaplastic large cell lymphoma
  • BIA-ALCL
  • Breast implant associated large cell lymphoma
  • Breast implants
  • Textured implants

Cite this

Cardoso, M. J. ; Wyld, L. ; Rubio, I. T. ; Leidenius, M. ; Curigliano, G. ; Cutuli, B. ; Marotti, L. ; Biganzoli, L. / EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. In: Breast. 2019 ; Vol. 44. pp. 90-93.
@article{36a7b12d355243d2b4d322236c3ae792,
title = "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants",
abstract = "During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally. We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it. We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL.",
keywords = "ALCL, Anaplastic large cell lymphoma, BIA-ALCL, Breast implant associated large cell lymphoma, Breast implants, Textured implants",
author = "Cardoso, {M. J.} and L. Wyld and Rubio, {I. T.} and M. Leidenius and G. Curigliano and B. Cutuli and L. Marotti and L. Biganzoli",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.breast.2019.01.011",
language = "English",
volume = "44",
pages = "90--93",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Blackwell Publishing Ltd",

}

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. / Cardoso, M. J.; Wyld, L.; Rubio, I. T.; Leidenius, M.; Curigliano, G.; Cutuli, B.; Marotti, L.; Biganzoli, L.

In: Breast, Vol. 44, 01.04.2019, p. 90-93.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants

AU - Cardoso, M. J.

AU - Wyld, L.

AU - Rubio, I. T.

AU - Leidenius, M.

AU - Curigliano, G.

AU - Cutuli, B.

AU - Marotti, L.

AU - Biganzoli, L.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally. We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it. We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL.

AB - During the last two decades the number of breast implants used in aesthetic, oncologic and risk reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. Whilst the majority of cases are localised and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. The evidence linking BIA-ALCL to implant surface texturing, as the majority of cases were diagnosed in patients with textured implants, has raised concerns about the long term safety of these devices resulting in patient and regulatory authority concerns globally. We hereby present the current published knowledge about the link between BIA-ALCL and implant surface texture and a review of current regulatory and professional body advice across Europe, which may enable a better understanding of this rare disease, how to manage and ultimately prevent it. We conclude by giving EUSOMA recommendation, towards the unnecessary change in attitudes towards implant based surgery, according to the most recent available published evidence as long as patients are properly informed about the risk of BIA-ALCL.

KW - ALCL

KW - Anaplastic large cell lymphoma

KW - BIA-ALCL

KW - Breast implant associated large cell lymphoma

KW - Breast implants

KW - Textured implants

UR - http://www.scopus.com/inward/record.url?scp=85060944114&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2019.01.011

DO - 10.1016/j.breast.2019.01.011

M3 - Article

VL - 44

SP - 90

EP - 93

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

ER -